TBE vaccine

from Wikipedia, the free encyclopedia

A TBE vaccine is a vaccine against the TBE virus .

properties

TBE vaccines consist of formalin - inactivated TBE viruses that have been cultivated on CEF cells . A dose of TBE-Immune for adults contains 2.4 μg of antigen , Encepur 1.5 μg, and children each half. It works against all three subtypes of the TBE virus (European, Siberian and Far Eastern subtype). The TBE vaccines approved in the EU are administered intramuscularly three times during an initial immunization . The first booster vaccination is recommended in the EU after three years, further vaccinations every 5 years for people under 60 years of age and every 3 years for people over 60 years of age. The TBE vaccine is on the World Health Organization's list of Essential Medicines . A passive immunization against the TBE virus is no longer permitted based on complicated clinical courses since 2003 in the EU. TBE vaccine is not approved in the USA, but in Canada.

immunology

The inactivated TBE vaccines produce neutralizing antibodies that protect 99% of those vaccinated against infection for three years after three vaccinations. Seropositivity is defined as an ELISA titer of 126 VIE U / ml or an NT titer of 1: ≥10. A titer of over 125 IU / mL is rated as protective. The time interval before a booster vaccination is not determined by a serological control of the titre, but is defined at fixed time intervals.

Side effects

Common side effects include pain at the injection site 1–4 days after vaccination (45%), increase in temperature (5–6%), headache, fatigue, malaise, gastrointestinal discomfort, joint and limb pain.

Trade names

Trade names for TBE vaccines are TBE- Immun (EU, vaccine strain Neudörfl ), Encepur (EU, vaccine strain K23 ), TBE-Moscow (Russia), EnceVir (Russia). In addition, there are lower-dose vaccines for children such as TBE- Immun Junior and Encepur Children .

literature

  • KL Mansfield, N. Johnson, LP Phipps, JR Stephenson, AR Fooks, T. Solomon: Tick-borne encephalitis virus - a review of an emerging zoonosis. In: The Journal of general virology. Volume 90, Pt 8 August 2009, pp 1781-1794, doi : 10.1099 / vir.0.011437-0 , PMID 19420159 .

Individual evidence

  1. ↑ a b c d e Centers for Disease Control : Tick-borne encephalitis . Retrieved August 11, 2016.
  2. ^ A b World Health Organization : Vaccines against tick-borne encephalitis: WHO position paper. In: Relevé épidémiologique hebdomadaire / Section d'hygiène du Secrétariat de la Société des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. Volume 86, Number 24, June 2011, pp. 241-256, PMID 21661276 .
  3. ↑ WHO Model List of Essential Medicines . In: World Health Organization . October 2013. Retrieved April 22, 2014.
  4. ↑ a b c d e Robert Koch Institute : TBE vaccination . Retrieved August 11, 2016.
  5. ↑ IJ Amanna, MK Slifka: Contributions of humoral and cellular immunity to vaccine-induced protection in humans. In: Virology (2011), Volume 411, Issue 2, pp. 206-215. doi : 10.1016 / j.virol.2010.12.016 . PMID 21216425 . PMC 3238379 (free full text).